Johnson & Johnson

History

1873–1885: Before Johnson & Johnson

Robert Wood Johnson began his professional training at age 16 as a pharmaceutical apprentice at an apothecary run by his mother's cousin, James G. Wood, in Poughkeepsie, New York. Johnson co-founded his own company with George Seabury in 1873. The New York-based Seabury & Johnson became known for its medicated plasters. Robert Wood Johnson represented the company at the 1876 World's Fair. There he heard Joseph Lister's explanation of a new procedure: antiseptic surgery. Johnson parted ways with his business partner Seabury in 1885.

1886: Founding of Johnson & Johnson

Robert Wood Johnson joined his brothers, James Wood Johnson and Edward Mead Johnson, and created a line of ready-to-use sterile surgical dressings in 1886. They founded Johnson & Johnson in 1886 with 14 employees, eight women and six men. Johnson & Johnson opened its first factory building in the old Janeway and Carpenter factory on Neilson Street in New Brunswick, New Jersey.

They manufactured sterile surgical supplies, household products, and medical guides. Those products initially featured a logo that resembled the signature of James Wood Johnson. Robert Wood Johnson served as the first president of the company.

1887–1942: Early history

The company sold medicated plasters such as Johnson & Johnson's Black Perfect Taffeta Court Plaster and also manufactured the world's first sterile surgical products, including sutures, absorbent cotton, and gauze. The company published "Modern Methods of Antiseptic Wound Treatment", a guide on how to do sterile surgery using its products, and in 1888, distributed 85,000 copies to doctors and pharmacists across the United States. The manual was translated into three languages and distributed worldwide. The first commercial first aid kit was designed in 1888 to support railroad construction workers, who were often hundreds of miles from medical care. The kits included antiseptic emergency supplies and directions for field use. In 1901, the company published the Handbook of First Aid, a guide on applying first aid.

In 1889, the company hired pharmacist Fred Kilmer as its first scientific director, who led its scientific research and wrote educational manuals. Kilmer's first achievement as scientific director was developing the industrial sterilization process. He was employed at the company until 1934.

Johnson & Johnson had more than 400 employees and 14 buildings by 1894. In 1894, the company began producing Johnson's Baby Powder, the company's first baby product.

The company introduced the world's first maternity kit in 1894 to aid at-home births, called Dr. Simpson's Maternity Packet, presumably after Scottish obstetrician James Young Simpson. The kit included a washcloth; safety pins; sterile sutures, sponges, and gauze; antiseptic soap; an obstetric sheet and ligatures; flannel to wrap the baby in; and a chart for keeping birth records. The products were later marketed separately, including "Lister's Towels", the world's first mass-produced sanitary napkins. Kilmer wrote "Hygiene in Maternity", an instructional guide for mothers before and after delivery. In 1904, the company expanded its baby care products with "Lister's Sanitary Diapers", a diaper product for infants.

During the Spanish–American War, Johnson & Johnson developed and donated 300,000 packaged compressed surgical dressings for soldiers in the field and created a trauma stretcher for field medics. The company donated its products in disaster relief efforts of the 1900 Galveston hurricane and the 1906 San Francisco earthquake.

Johnson & Johnson vaccinated all of its employees against smallpox during the 1901 smallpox epidemic. The firm employed more than 1,200 people by 1910. Women accounted for half of the company's workforce and led a quarter of its departments.

Robert Wood Johnson died in 1910, and he was succeeded as president of the company by his brother James Wood Johnson.

During World War I, Johnson & Johnson factories increased production to meet wartime demands for sterile surgical products. In 1916, the company acquired Chicopee Manufacturing Company in Chicopee Falls, Massachusetts, to meet demand. Near the end of World War I, the 1918 flu pandemic broke out. The company invented and distributed an epidemic mask that helped prevent the spread of the flu.

In 1919, Johnson & Johnson opened the Gilmour Plant near Montreal, its first factory outside the United States, which produced surgical products for international customers. In 1924 the company's first overseas manufacturing facility was opened in Slough, England.

In 1920, Earle Dickson combined two Johnson & Johnson products, adhesive tape and gauze, to create the first commercial adhesive bandage. Band-Aid Brand Adhesive Bandages began sales the following year. In 1921, the company released Johnson's Baby Soap. Named after its Massachusetts facility, Johnson & Johnson built a textile mill and company town, Chicopee, outside Gainesville, Georgia. In the 1930s, the company expanded operations to Argentina, Brazil, Mexico, and South Africa. In 1931, Johnson & Johnson introduced the first prescription contraceptive gel marketed as Ortho-Gynol.

Robert Wood Johnson II became president of the company in 1932.

During The Great Depression Johnson & Johnson kept all its workers employed and raised wages by 5%. In 1933, Robert Wood Johnson II wrote a letter to Franklin D. Roosevelt, calling for a federal law to increase wages and reduce hours for all American workers. The company also opened a new facility in Chicago during that period. Johnson wrote and distributed "Try Reality: A Discussion of Hours, Wages, and The Industrial Future" to persuade business leaders to follow his lead, advocating that business is more than profit and that companies have responsibilities to consumers, employees, and society. In "Try Reality", the section titled "An Industrial Philosophy" would later become the company's credo.

In 1935, Johnson's Baby Oil was added to its line of baby products. Both male and female Johnson & Johnson employees were drafted and enlisted during World War II. The company ensured no one would lose their job when they returned home. Robert Wood Johnson II was appointed head of the Smaller War Plants Corporation in Washington, D.C. His work ensured U.S. factories with under 500 employees were awarded government contracts.

1943: Credo and going public

In 1943, as the company was preparing for its initial public offering (IPO), Robert Wood Johnson wrote what the company would call, "Our Credo", a defining document that has been used to guide the company's decisions over the years. The company completed its IPO and became a public company in 1944.

In 1943, Vesta Stoudt identified a need for waterproof tape for ammunition boxes in World War Two. She wrote to Franklin D. Roosevelt with the idea; the president commissioned Revolite, a subsidiary of Johnson & Johnson at the time, to develop and manufacture a cloth-based adhesive tape.

1944–1999: Acquisitions and international expansion

In 1944, the company began selling Johnson's Baby Lotion. The same year, the company established Ethicon Suture Laboratories. In 1947, G. F. Merson Ltd. was acquired to expand the company's suture business in the United Kingdom. The company was rebranded and absorbed into Ethicon.

Johnson & Johnson chairman of the board, Robert Wood Johnson, published Or Forfeit Freedom, in 1947. The book outlined that businesses need to develop sustainable methods of using natural resources for the future of business and the planet.

In 1955, Ethicon developed a micro-point reverse-cutting ophthalmic needle attached to the suture. Micro-point surgical needles and sutures allowed for advances in modern vision surgery. In 1956, the company opened its first Asia-based operating company in the Philippines. The following year, an operating company opened in India.

In 1959, Johnson & Johnson acquired McNeil Laboratories. A year later, the company sold Tylenol for the first time without a prescription. In the same year, Cilag Chemie joined Johnson & Johnson as Cilag.

In 1961, Johnson & Johnson acquired Janssen Pharmaceuticals, which had been founded in 1953 by Belgian scientist Paul Janssen, the inventor of Fentanyl.

In 1963, Philip B. Hofmann succeeded Robert Wood Johnson as chairman and CEO. He was the first non-Johnson family member to become chief executive. Hofmann also helped found the Robert Wood Johnson Foundation. In the same year, the Food and Drug Administration approved a synthetic hormone contraceptive pill, Ortho-Novum.

In 1965, Johnson & Johnson acquired Codman & Shurtleff. The acquired company produced neurovascular devices and neurosurgery technologies. In 1968, the company developed the RhoGAM vaccine. The vaccine prevented Rh hemolytic disease in newborns.

In 1969, Ortho Diagnostics, a company subsidiary, launched the Sickledex Tube Test for detecting anemia. The same year, the FDA approved the Johnson & Johnson arterial graft. In 1971, the company launched Hapindex Diagnostic Test, a rapid hepatitis B test for blood donors. The test was developed to prevent the spread of hepatitis B through blood transfusions.

In the 1970s, Johnson & Johnson hired Henry N. Cobb from Pei Cobb Freed & Partners to design its new headquarters. The firm designed Johnson & Johnson Plaza across the railroad tracks from the older section of the Johnson & Johnson campus.

In 1973, Richard Sellars became chairman and CEO of Johnson & Johnson. In 1976, James E. Burke became the company's chairman and CEO. During Burke's tenure, he managed the 1982 Tylenol tampering incident. It became a case study on crisis management. Under his leadership, the company recalled 31 million bottles of Tylenol, relaunched the product with a triple tamper-evident seal, and urged consumers not to use if tampered with. These practices became the pharmaceutical and packaged food industry norm.

Johnson & Johnson opened operating companies in China and Egypt in 1985. In 1987, Acuvue contact lenses became the first disposable contact lenses available to consumers. The lenses lasted up to one week, reducing the cost of contact lenses. In the same year, the company launched One Touch, a blood glucose monitoring system. In 1989, Ralph S. Larsen was appointed chairman and CEO of the company.

After the dissolution of the Soviet Union, Johnson & Johnson expanded into eastern Europe. By 1991, the company had a presence in Hungary, Russia, the Czech Republic, and Poland. In the 1990s, the company acquired many familiar consumer health brands that made up the Johnson & Johnson family of companies. These acquisitions included Clean & Clear, Neutrogena, Motrin, and Aveeno.

Johnson & Johnson opened an operating company in Israel in 1996. In 1997, Johnson & Johnson acquired Biosense Webster. DePuy was acquired by Johnson & Johnson in 1998, rolling it into the Medtech business group.

2000–present

William C. Weldon was appointed chairman and CEO of the company in 2002. In 2003, Ethicon launched Vicryl Plus Antibacterial Sutures. The products prevent post-surgery infection within stitches. In 2006, Johnson & Johnson acquired Pfizer's consumer healthcare business and merged it with its consumer healthcare business group. The acquisition added brands like Listerine, Bengay, and Neosporin to the company's portfolio. In the same year, Johnson & Johnson's Janssen Pharmaceuticals, launched Prezista, a protease inhibitor for patients with failed previous HIV therapies.

In 2008, Johnson & Johnson acquired Mentor Corporation for $1 billion and merge its operations into Ethicon. In 2009, the company acquired HealthMedia, later renamed to Health & Wellness Solutions and the Human Performance Institute. In October 2010, J&J acquired Crucell for $2.4 billion. The subsidiary operates as the centre for vaccines, within Johnson & Johnson pharmaceuticals business group.

In 2012, Alex Gorsky became chairman and CEO of Johnson & Johnson. In November 2015, Biosense Webster, Inc. acquired Coherex Medical Inc. expanding the company's range of treatment options for patients with atrial fibrillation.

In 2017, Johnson & Johnson acquired Abbott Medical Optics from Abbott Laboratories for $4.325 billion, adding the new division into Johnson & Johnson Vision Care, Inc. in 2017. That same year, Johnson & Johnson acquired Actelion in a $30 billion deal, the largest ever purchase by the company. After the purchase, Johnson & Johnson spun off Actelion's research and development unit into a separate legal entity. In July 2017, Johnson & Johnson Vision Care, Inc acquired TearScience. In September 2017, the company acquired subscription-based contact lens startup Sightbox. In September of the same year Johnson & Johnson Medical GmbH acquired Emerging Implant Technologies GmbH, manufacturer of 3D-printed titanium interbody implants for spinal fusion surgery.

In March 2019, the FDA approved esketamine for the treatment of severe depression, which is marketed as Spravato by Janssen Pharmaceuticals. In 2019, Johnson & Johnson announced the release of photochromic contact lenses. The lenses adjust to sunlight and help eyes recover from bright light exposure faster. The lenses contain a photochromic additive that adapts visible light amounts filtered to the eyes and are the first to use such additives.

In November 2020, Johnson & Johnson acquired Momenta Pharmaceuticals for $6.5 billion.

In January 2022, Joaquin Duato became CEO of Johnson & Johnson.

In December 2022, Johnson & Johnson acquired cardiovascular medical technology company Abiomed Inc. for $16.6 billion.

Johnson & Johnson began the separation of their consumer healthcare business segment in November 2021. In the split, Johnson & Johnson will retain the Johnson & Johnson name for prescription drugs and medical devices, while the second company will sell consumer health products and take over the Neutrogena, Aveeno, Tylenol, Listerine, Johnson's, Band-Aid and other brands. In September 2022, Johnson & Johnson chose Kenvue as the new name for its Consumer Health business. Kenvue went public through an IPO in May 2023, with Johnson & Johnson maintaining a controlling stake of around 91 percent. On July 24, 2023, Johnson & Johnson launched an exchange offer to split-off Kenvue. Following the completion of the exchange offer, Johnson & Johnson will retain approximately 9.5% of the outstanding shares of Kenvue common stock.In 2024, Johnson & Johnson sold off its remaining 9.5% stake in Kenvue, its former consumer products business.

Johnson & Johnson holds a patent on the tuberculosis-treating drug bedaquiline, with secondary patents in at least 25 out of 43 countries with a high burden of tuberculosis blocking affordable generic versions of the drug, preventing millions of people from accessing the life-saving treatment. Though the patent was set to expire in many countries in 2023, Johnson & Johnson applied to extend the patent. On July 13, 2023, Stop TB Partnership announced that after negotiations with Johnson & Johnson, they had been granted licenses to produce generic versions of the drug.

Johnson & Johnson announced several acquisitions in 2024: Ambrx Biopharma for $2 billion (in January), Shockwave Medical for $13.1 billion (in April), and Proteologix for $850 million (in May). In 2024, Johnson & Johnson MedTech released Polyphonic, a digital surgical platform. The platform features surgery planning, surgical video, and telepresence services for laparoscopic surgeries.

In January 2025, Johnson & Johnson announced it would acquire neurological drug maker Intra-Cellular Therapies for $14.6 billion, a company specializing in medications for behavioral disorders, including schizophrenia, depression, and bipolar disorder.

Coronavirus (COVID-19) response

Johnson & Johnson committed over $1 billion toward the development of a not-for-profit COVID-19 vaccine in partnership with the Biomedical Advanced Research and Development Authority (BARDA) Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS). Paul Stoffels of Johnson & Johnson said, "In order to go fast, the people of Johnson & Johnson are committed to do this and all together we say we're going to do this not for profit. That's the fastest and the best way to find all the collaborations in the world to make this happen so we commit to bring this at a not-for-profit level."

Janssen Vaccines, in partnership with Beth Israel Deaconess Medical Center (BIDMC), is responsible for developing the vaccine candidate, based on the same technology used to make its Ebola vaccine. The vaccine candidate is expected to enter phase 1 human clinical study in September 2020.

Demand for the product Tylenol surged two to four times normal levels in March 2020. In response, the company increased production globally. For example, the Tylenol plant in Puerto Rico ran 24 hours a day, seven days a week.

In response to the shortage of ventilators, Ethicon, with Prisma Health, made and distributed the VESper Ventilator Expansion Splitter, which uses 3D printing technology, to allow one ventilator to support two patients.

Janssen COVID-19 vaccine

Main article: Janssen COVID-19 vaccine

In June 2020, Johnson & Johnson and the National Institute of Allergy and Infectious Diseases (NIAID) confirmed its intention to start a clinical trials of J&J's vaccine in September 2020, with the possibility of Phase 1/2a human clinical trials starting at an accelerated pace in the second half of July.

On August 5, 2020, the US government agreed to pay more than $1 billion to Johnson & Johnson (medical device company) for the production of 100 million doses of COVID-19 vaccine. As part of the agreed-upon deal, the U.S. can order up to 200 million additional doses of SARS-CoV-2 vaccine.

In September 2020, Johnson & Johnson started its 60,000-person phase 3 adenovirus-based vaccine trial. The trial was paused on October 12, 2020, because a volunteer became ill, but the company said it found no evidence that the vaccine had caused the illness and announced on October 23, 2020, that it would resume the trial.

In April 2021, the company reported that its COVID-19 vaccine achieved $100 million sales in the first quarter, accounting for less than 1% of its total revenue.

Jnj acquisition history

• Johnson & Johnson (Founded 1886)
  • Chicopee Manufacturing Company (Acq 1916)
  • Ethicon (Founded as G.F.Mersons Limited 1915, Acq 1947)
    • Mentor Worldwide (Founded 1969 Acq 2009)
  • McNeil Pharmaceutical(Acq 1959)
    • Ortho Pharmaceutical(Merged 1993)
  • Cilag Chemie (Acq 1959)
  • Janssen Pharmaceuticals (Acq 1961)
  • Codman & Shurtleff (Acq 1965)
  • Frontier Contact Lenses (Acq 1981)
  • Neutrogena (Acq 1994)
  • Biosense Webster (Acq 1997)
  • DePuy Manufacturing (Acq 1998)
    • ACE Medical (Acq 1994)
    • AcroMed (Acq 1998)
  • Centocor Biotech (Acq 1999)
  • Mentor Worldwide (Acq 2008)
  • Crucell (Acq 2011)
    • Introgene (Merged 2000)
    • U-Bisys (Merged 2000)
    • SBL Vaccin (Acq 2006)
    • Berna Biotech (Acq 2005)
  • Synthes (Acq 2012)
    • Stratec Medical(Merger 2003)
  • Covagen (Acq 2014)
  • Coherex Medical Inc(Acq 2015)
  • Advanced Medical Optics(Acq 2017)
    • American Hospital Supply Corporation (Acq 1974)
    • VisX Inc.(Acq 2004)
    • WaveFront Sciences Inc.(Acq 2007)
    • IntraLase Corp.(Acq 2007)
    • Visiogen (Acq 2009)
    • OptiMedica(Acq 2013)
  • Actelion (Acq 2017)
    • CoTherix (Acq 2006)
  • TearScience (Acq 2017)
  • Momenta Pharmaceuticals (Acq 2020)
  • Abiomed(Acq 2022)
    • Impella CardioSystems AG (Acq 2005)
    • Breethe(Acq 2020)
    • preCARDIA(Acq 2021)
  • Ambrx Biopharma (Acq 2024)
  • Shockwave Medical (Acq 2024)
  • Proteologix (Acq 2024)
  • Intra-Cellular Therapies (Acq 2025)

Business segments

The company's business is divided into two business segments: Innovative Medicine and MedTech.

Johnson & Johnson Innovation, LLC (JJI) is a subsidiary of Johnson & Johnson. JJI focuses on early-stage, life science, and technology innovations to advance the company's research and development pipeline. JJI provides startups with sourcing, infrastructure, and capital equipment at JLABS, financing & venture capital at JJDC, Inc., and collaborations leading to the potential development of medical device technologies, pharmaceuticals, and therapeutics. There are 4 JJI Innovation Centers located in London, Shanghai, Boston (Cambridge), and the San Francisco Bay Area. There are 13 JLABS incubators located in the Bay Area (San Francisco and South San Francisco), Belgium (Beerse), Boston (Cambridge and Lowell), Houston (TMC), New York City, Philadelphia, San Diego, Shanghai, Toronto, and Washington, D.C.

Innovative Medicine

Main article: Janssen Pharmaceuticals

The Innovative Medicine (formerly known as pharmaceuticals) segment is focused on six therapeutic areas: immunology (rheumatoid arthritis, inflammatory bowel disease and psoriasis); infectious diseases (HIV/AIDS); neuroscience (mood disorders, neurodegenerative disorders and schizophrenia); oncology (solid tumours including lung cancer, prostate cancer and bladder cancer, and hematologic malignancies); cardiovascular, metabolism, retina (thrombosis and diabetes), and pulmonary hypertension (pulmonary arterial hypertension).

MedTech

The Cardiovascular & Specialty Solutions Group includes electrophysiology products that diagnose and treat cardiac arrhythmias; devices used in the endovascular treatment of hemorrhagic and ischemic stroke; solutions that focus on breast reconstruction and aesthetics, and ear, nose and throat procedures.

The orthopaedics portfolio is composed of specialties including joint reconstruction, trauma, extremities, craniomaxillofacial, spinal surgery and sports medicine, in addition to the VELYS digital surgery portfolio.

The surgery portfolio includes advanced surgical innovations and solutions such as sutures, staplers, energy devices, and advanced hemostats along with interventional ablation, surgical robotics, and digital solutions.

The Johnson & Johnson Vision portfolio includes contact lenses, intraocular lens, automated treatment for dry eye, and four brands of laser vision correction systems.

Finance

For the fiscal year 2024, Johnson & Johnson reported earnings of $14.07billion, with an annual revenue of $88.82 billion. Johnson & Johnson's shares traded at over $165 per share, and its market capitalization was valued at over $394billion in March 2025.

Pricing

In 2023, the Institute for Clinical and Economic Review (ICER) identified Darzalex (daratumumab), developed by Johnson & Johnson as one of five high-expenditure drugs that experienced significant net price increases without new clinical evidence to justify the hikes. Specifically, Darzalex's wholesale acquisition cost rose by approximately 7.6%, leading to an additional $190 million in costs to U.S. payers.

Corporate governance

As of January 2026, the members of the board of directors of Johnson & Johnson are Joaquin Duato, Mary C. Beckerle, Jennifer A. Doudna, Marillyn A. Hewson, Paula A. Johnson, Hubert Joly, Mark B. McClellan, John G. Morikis, Daniel E. Pinto, Mark A. Weinberger, Nadja Y. West, and Eugene A. Woods.

As of January 2026, the members of the executive committee of Johnson & Johnson are Joaquin Duato, Vanessa Broadhurst, Liz Forminard, Kristen Mulholland, John C. Reed, Tim Schmid, James Swanson, Jennifer Taubert, Kathy E. Wengel, and Joseph J. Wolk.

Joaquin Duato is chairman and chief executive officer.

Chairmen

• Robert Wood Johnson I (1887–1910)
• James Wood Johnson (1910–1932)
• Robert Wood Johnson II (1932–1963)
• Philip B. Hofmann (1963–1973)
• Richard B. Sellars (1973–1976)
• James E. Burke (1976–1989)
• Ralph S. Larsen (1989–2002)
• William C. Weldon (2002–2012)
• Alex Gorsky (2012–2022)
• Joaquin Duato (2023–present)

Ownership

Institutional Investors hold 73.57% of outstanding shares. The ten largest shareholders as of December 2024:

• The Vanguard Group (9.67%)
• BlackRock (8.36%)
• State Street Corporation (5.58%)
• Geode Capital Management (2.40%)
• Morgan Stanley (1.82%)
• JPMorgan Chase (1.61%)
• State Farm (1.32%)
• Northern Trust (1.28%)
• Norges Bank (1.26%)
• Wellington Management Group (1.01%)

Environmental record

Johnson & Johnson has set several goals to keep the company environmentally friendly and was ranked third among the largest US companies in Newsweeks "Green Rankings". Some examples are the reduction in water use, waste, and energy use and an increased level of transparency. Johnson & Johnson agreed to change its packaging of plastic bottles used in the manufacturing process, switching their packaging of liquids to non-polyvinyl chloride containers. The corporation is working with the Climate Northwest Initiative and the EPA National Environmental Performance Track program. As a member of the national Green Power Partnership, Johnson & Johnson operates the largest solar power generator in Pennsylvania at its site in Fort Washington, Pennsylvania.

Independent climate-data platforms show that most of Johnson & Johnson’s emissions come from its supply chain rather than from its own buildings. Tracenable and DitchCarbon estimate that "purchased goods and services" – the production of medicines, medical devices and packaging that J&J buys – accounts for about 72% of its Scope 3 emissions, roughly 4.8 million metric tons of CO₂e per year. This matches wider health-care research finding that about 70% of the sector’s climate footprint is embedded in global supply chains for drugs, equipment and other goods.

Recalls and litigation

1982 Chicago Tylenol murders

Main article: Chicago Tylenol murders

On September 29, 1982, a "Tylenol scare" began when the first of seven individuals died in Chicago metropolitan area, after ingesting Extra Strength Tylenol that had been deliberately laced with cyanide. Within a week, the company pulled 31 million bottles of capsules back from retailers, making it one of the first major recalls in American history. The incident led to reforms in the packaging of over-the-counter substances and to federal anti-tampering laws. The case remains unsolved and no suspects have been charged. Johnson & Johnson's quick response, including a nationwide recall, was widely praised by public relations experts and the media and was the gold standard for corporate crisis management.

2010 children's product recall

Main article: 2010 Johnson & Johnson children's product recall

On April 30, 2010, McNeil Consumer Healthcare, a subsidiary of Johnson & Johnson, voluntarily recalled 43 over-the-counter children's medicines, including Tylenol, Tylenol Plus, Motrin, Zyrtec and Benadryl. The recall was conducted after a routine inspection at a manufacturing facility in Fort Washington, Pennsylvania, United States, revealed that some "products may not fully meet the required manufacturing specifications". Affected products may contain a "higher concentration of active ingredients" or exhibit other manufacturing defects. Products shipped to Canada, Dominican Republic, Mexico, Guam, Guatemala, Jamaica, Puerto Rico, Panama, Trinidad and Tobago, the United Arab Emirates, Kuwait and Fiji were included in the recall. In a statement, Johnson & Johnson said "a comprehensive quality assessment across its manufacturing operations" was underway.{{Cite news

2010 hip-replacement recall

Main article: 2010 DePuy Hip Recall

On August 24, 2010, DePuy, a subsidiary of American giant Johnson & Johnson, recalled its ASR (articular surface replacement) hip prostheses from the market. DePuy said the recall was due to unpublished National Joint Registry data showing a 12% revision rate for resurfacing at five years and an ASR XL revision rate of 13%. All hip prostheses fail in some patients, but it is expected that the rate will be about 1% a year. Pathologically, the failing prosthesis had several effects. Metal debris from wear of the implant led to a reaction that destroyed the soft tissues surrounding the joint, leaving some patients with long term disability. Ions of cobalt and chromiumthe metals from which the implant was madewere also released into the blood and cerebrospinal fluid in some patients.

In March 2013, a jury in Los Angeles ordered Johnson & Johnson to pay more than $8.3million in damages to a Montana man in the first of more than 10,000 lawsuits pending against the company in connection with the now-recalled DePuy hip.

Some lawyers and industry analysts have estimated that the suits ultimately will cost Johnson & Johnson billions of dollars to resolve.

2010 Tylenol recall

In 2010 and 2011, Johnson & Johnson voluntarily recalled some over-the-counter products, including Tylenol, due to an odor caused by tribromoanisole. In this case, 2,4,6-tribromophenol was used to treat wooden pallets on which product packaging materials were transported and stored.

Shareholders lawsuit

In 2010 a group of shareholders sued the board for allegedly failing to take action to prevent serious failings and illegalities since the 1990s, including manufacturing problems, bribing officials, covering up adverse effects and misleading marketing for unapproved uses. The judge initially dismissed the case in September 2011, but allowed the plaintiffs opportunity to refile at a later time. In 2012 Johnson and Johnson proposed a settlement with the shareholders, whereby the company would institute new oversight, quality and compliance procedures binding for five years.

Illegal marketing of Risperdal

Juries in several US states have found J&J guilty of concealing the adverse effects of Janssen Pharmaceuticals' antipsychotic medication Risperdal, produced by its unit, to promote it to doctors and patients as better than cheaper generics, and of falsely marketing it for treating patients with dementia. States that have awarded damages include Texas ($158million), South Carolina ($327million), Louisiana ($258million), and most notably Arkansas ($1.2billion).

In 2010, the United States Department of Justice joined a whistleblowers suit accusing the company of illegally marketing Risperdal through Omnicare, the largest company supplying pharmaceuticals to nursing homes. The allegations include that J&J were warned by the FDA to not promote Risperdal as effective and safe for elderly patients, but they did so, and that they paid Omnicare to promote the drug to care home physicians. The settlement was finalized on November 4, 2013, with J&J agreeing to pay a penalty of around $2.2billion, "including criminal fines and forfeiture totaling $485million and civil settlements with the federal government and states totaling $1.72billion".

Johnson & Johnson has also been subject to congressional investigations related to payments given to psychiatrists to promote its products and ghost write articles, notably Joseph Biederman and his pediatric bipolar disorder research unit.

Foreign bribery

In 2011, J&J settled litigation brought by the US Securities and Exchange Commission under the Foreign Corrupt Practices Act and paid around $70M in disgorgement and fines. J&J's employees had given kickbacks and bribes to doctors in Greece, Poland, and Romania to obtain business selling drugs and medical devices and had bribed officials in Iraq to win contracts under the Oil for Food program. J&J fully cooperated with the investigation once the problems came to light.

Consumer fraud settlements

In May 2017, J&J reached an agreement to pay $33million to several states to settle consumer fraud allegations in some of the company's over-the-counter drugs.

Use of the Red Cross symbol

Johnson & Johnson registered the Red Cross as a U.S. trademark for "medicinal and surgical plasters" in 1905 and has used the design since 1887. The Geneva Conventions, which reserved the Red Cross emblem for specific uses, were first approved in 1864 and ratified by the United States in 1882. However, the emblem was not protected by U.S. law for the use of the American Red Cross (ARC) and the U.S. military until after Johnson & Johnson had obtained its trademark. A clause in this law (now 18 U.S.C. 706) permits this pre-existing use of the Red Cross to continue.

A declaration made by the U.S. upon its ratification of the 1949 Geneva Conventions includes a reservation that pre-1905 U.S. domestic uses of the Red Cross, such as Johnson & Johnson's, would remain lawful as long as the cross is not used on "aircraft, vessels, vehicles, buildings or other structures, or upon the ground", i.e., uses which could be confused with its military uses. This means that the U.S. did not agree to any interpretation of the 1949 Geneva Conventions that would overrule Johnson & Johnson's trademark. The American Red Cross continues to recognize the validity of Johnson & Johnson's trademark.

In August 2007, Johnson & Johnson filed a lawsuit against the ARC, demanding that the charity halt the use of the red cross symbol on products it sells to the public, though the company takes no issue with the charity's use of the mark for nonprofit purposes. In May 2008, the judge in the case dismissed most of Johnson & Johnson's claims, and a month later the two organizations announced a settlement had been reached in which both parties would continue to use the symbol.

Boston Scientific lawsuits

Since 2003, Johnson & Johnson and Boston Scientific have both claimed that the other had infringed on their patents covering heart stent medical devices. The litigation was settled when Boston Scientific agreed to pay $716million to Johnson & Johnson in September 2009 and an additional $1.73billion in February 2010. Their dispute was renewed in 2014, now on the grounds of a contract dispute.

Patent-infringement case against Abbott

In 2007, Johnson & Johnson sued Abbott Laboratories over the development and sale of the arthritis drug Humira, claiming Abbott used technology licensed exclusively to Johnson & Johnson's Centocor division. Johnson & Johnson won the court case, and in 2009 Abbott was ordered to pay Johnson & Johnson $1.17billion in lost revenues and $504million in royalties. The judge also added $175.6million in interest to bring the total to $1.84billion. This was the largest patent-infringement award in U.S. history In 2010 Abbott appealed the verdict

Vaginal mesh implants

Tens of thousands of women worldwide have taken legal action against Johnson & Johnson after suffering serious complications following a vaginal mesh implant procedure. In Australia, more than 700 women began a class action against the company in the Federal Court of Australia in 2017, telling the court they "suffered irreparable, debilitating pain after the devices began to erode into surrounding tissue and organs, causing infections and complications". The class action alleged that Johnson & Johnson, which "aggressively marketed" the implants "failed to properly warn patients and surgeons of the risk, or test the devices adequately". Emails between executives show the company was aware of the risks in 2005 but still went ahead and made the product available. In November 2019 the Federal Court of Australia found Johnson & Johnson negligent. The judgment was appealed, with the appeals court upholding all findings of Justice Anna Katzman. Ethicon then sought a High Court decision but this was not permitted by the High Court of Australia. Subsequently (September 2022) a A$300,000,000 compensation agreement was reached between Shine Lawyers and J&J but this agreement remains subject to approval by the Federal Court of Australia.

In the US in 2016 the U.S. states of California and Washington filed a lawsuit against the company, accusing it of deception. In October 2019, the company and its subsidiary, Ethicon, Inc. reached a settlement with 41 states and the District of Columbia, with no admission of liability, in a suit alleging deceptive marketing of transvaginal surgical-mesh devices. The suit also alleges that the company failed to disclose risks associated with the product, which J&J pulled from the US market in 2012. The amount settled in the suit was about $117million.

Baby powder

J&J has been the subject of over 60,000 lawsuits claiming that its baby powder causes ovarian cancer. The lawsuits focus on claims that the talc-based powder is contaminated with asbestos, a known carcinogen commonly found in places where talc is mined.

In 2016, J&J was ordered to pay $72million in damages to the family of Jacqueline Fox, a 62-year-old woman who died of ovarian cancer in 2015. The company said it would appeal. A year later, over 1,000 U.S. women had sued J&J for covering up the possible cancer risk from its Baby Powder product. The company says that 70% of its Baby Powder is used by adults. Later that year, a California jury ordered Johnson & Johnson to pay $417million to a woman who claimed she developed ovarian cancer after using the company's talc-based products like Johnson's Baby Powder for feminine hygiene. The verdict included $70million in compensatory damages and $347million in punitive damages. J&J said they would appeal the verdict. The Missouri Eastern District appeals court later negated a $72million jury verdict in the Jacqueline Fox lawsuit, ruling it lacked jurisdiction in Missouri because of a U.S. Supreme Court decision that imposed limits on where injury lawsuit can be filed. Subsequently, this ruling killed three other recent St. Louis jury verdicts of more than $200million combined. Fox, 62, of Birmingham, Alabama, died in 2015, about four months before her trial was held in St. Louis Circuit Court. She was among 65 plaintiffs, of whom only two were from Missouri.

A St. Louis jury awarded nearly $4.7billion in damages to 22 women and their families in 2018 after they claimed that asbestos in Johnson & Johnson talcum powder caused their ovarian cancer. In August, J&J said that it removed several chemicals from baby powder products and re-engineered them to make consumers more confident that products were safer for children. The company was forced to release internal documents with 11,700 people suing J&J over cancers allegedly caused by baby powder. The documents showed that the company had known about asbestos contamination since at least as early as 1971 and had spent decades finding ways to conceal the evidence from the public.

The company lost its request to reverse a jury verdict that ruled in favor of the accusers, which required the company to pay $4.14billion in punitive damages and $550million in compensatory damages. A large study performed in 2003 found that ovarian cancer risk increased from a baseline of 0.0121% to 0.0161% in people who reported regularly using talc in the genital area. Two more studies over the next twelve years, which also relied on self-reporting, had similar results; however, none of the three studies showed a relationship between how long someone used talc and how much their cancer risk increased, which is expected in experiments with carcinogens and other toxic substances (see dose–response relationship).

Conversely, a St. Louis jury ruled in favor of Johnson & Johnson in the case of a single plaintiff who had used the company's talc-containing baby powder for thirty years with a similar claim. The company's CEO, Alex Gorsky, declined to appear at a United States congressional hearing on the safety of J&J's Baby Powder and other talc-based cosmetics. J&J spokesman Ernie Knewitz said that the subcommittee had rejected the company's offers to send a talc testing expert or a J&J executive in charge of consumer products. In response to declining demand, J&J announced it would discontinue the sale of talc-based baby powder in the United States and Canada in 2020, but would continue to sell it in other markets. In a statement, the company said that the existing retail inventory of the talc-based powder will sell until it runs out, while the company's cornstarch-based baby powder will continue to sell in the United States and Canada.

The Supreme Court of Missouri refused to consider J&J's appeal of a $2.12 billion damages award to women who blamed their ovarian cancer on its talc-based products.

The Supreme Court of the United States also refused to consider an appeal from J&J, leaving in place a judgment from a state appeal court that had cut the original award to $2.1 billion. Two of the justices had to recuse: Samuel Alito because either he and/or his wife owning or recently owning stock in J&J, and Brett Kavanaugh, whose father led an industry group lobbying against safety warnings on talc products. Representing the affected women during the trial, Mark Lanier remarked that the Supreme Court's decision sent "a clear message to the rich and powerful: You will be held to account when you cause grievous harm under our system of equal justice under law." J&J had argued that the combined claims in the St. Louis trial were too different, yet the short jury deliberation and identical payouts were, therefore, a violation of the company's due process and also that the high punitive award was unconstitutional.

In 2021, Johnson & Johnson subsidiary LTL Management LLC, using a process called a Texas divisional merger, filed for Chapter 11 bankruptcy in North Carolina. The process allowed by Texas law lets a company create a separate subsidiary to take over liabilities, with the existing company operating normally. The new company, with a different name, can locate in a state such as North Carolina where bankruptcy laws are different, and then declare bankruptcy, paying less than the original company would have. In the case of LTL, a $2 billion trust will be created, compared to $25 billion if Johnson & Johnson had declared bankruptcy. According to the filing, a company known as Old JJCI took on the baby powder related liabilities in 1979, while Johnson & Johnson remained a defendant. LTL and New JJCI were created with LTL taking the baby powder related liabilities and some assets, and New JJCI taking the remaining assets. Johnson & Johnson says LTL is now based in New Jersey.

The company announced that it would stop making talc-based powder by 2023 and replace it with cornstarch-based powders. The company says the talc-based powder is safe to use and does not contain asbestos.

Lawsuits showed connections between Johnson & Johnson and the Holmesburg Prison experiments.

In 2023, the number of lawsuits regarding talc-based baby powder exceeded 40,000 as more claimants came forward to say that the company's product caused them to have cancer. Johnson & Johnson offered $9 billion to settle all the lawsuits against the company, up from the previous figure of $2 billion.

In February 2025, as the number of talc-based powder related lawsuits sits at over 62,000, Johnson & Johnson offered a settlement of $10 billion to end litigation, funded by a subsidiary's filing for Chapter 11 bankruptcy, reliant on the approval from Houston bankruptcy judge, Judge Christopher Lopez. While the proposal showed significantly more support compared to their last bankruptcy attempts, there are accusations of the company pushing against negative votes, and widely accepting positive ones. Adam Silverstein, an attorney representing plaintiffs rejecting the proposal, branded the move as a "blatant double standard" in a statement to Lopez. The judged ultimately denied J&J's attempt.

In October 2025, a Los Angeles court ordered J&J to pay $966 million to the family of a woman who died from mesothelioma in 2021. The ruling came days after a South Carolina court rejected a lawsuit of a man that similarly claimed asbestos fibers in baby powder caused his cancer. J&J called the ruling unconstitutional and said it would appeal. Since this ruling, J&J has seen a 17% rise in talc cancer related suits.

Opioid epidemic

By 2018, the company had become embroiled in the opioid epidemic in the United States and had become a target of lawsuits. Over 500 opioid-related cases have been filed as of May 2018 against J&J and its competitors. In Idaho, J&J is part of a lawsuit accusing the company for being partially to blame for opioid-related overdose deaths. The first major trial began in Oklahoma in May 2019. On August 26, 2019, the Oklahoma judge ordered J&J to pay $572million for their part in the opioid crisis, and in October J&J paid $20.4million to two Ohio counties fighting the opioid epidemic. In January 2022, Johnson & Johnson agreed to pay up to $5 billion as part of a $26 billion settlement which included McKesson, AmerisourceBergen, and Cardinal Health. Had the states gone to court, the companies could have faced up to $95 billion in penalties.

Northeastern Ohio Settlement

In October 2019, the company agreed to a settlement of $20.4million with northeastern Ohio's most populous counties of Cuyahoga (containing Cleveland) and Summit (Akron). The settlement allows the company avoidance of a trial accusing J&J and many other pharmaceutical manufacturers of helping to spark the US opioid epidemic. The trial was thought to be an indicator for thousands of opioid-related lawsuits against many drug manufacturers. The arrangement, which contains no admission of liability by the company, provides the counties $10million in cash, $5million for legal expenses and $5.4million in contributions to opioid-related nonprofit organizations in the counties.

Public-private engagement

Johnson & Johnson and its subsidiaries engage with the public and private sectors in a variety of settings including to promote research and development, academic funding, event sponsorship, philanthropy, and political lobbying.

Academia

• J&J is a matching gift donor to the Institute for Advanced Study.

Activism

• J&J is a corporate partner of Human Rights Campaign, a large LGBT advocacy group.
• J&J is a financial supporter of Women Deliver.

Political lobbying

Johnson & Johnson is engaged in various forms of lobbying in the United States, Canada and internationally, including through corporate philanthropy and membership in lobbying organizations.

• J&J is one of the largest donors to the Foundation for the National Institutes of Health (FNIH), having donated $5–10 million from 2000 to 2020.
• J&J is a partner of the Pandemic Action Network.
• J&J is a member company of the Biotechnology Innovation Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA), trade associations that lobby the U.S. Government on behalf of the Biotechnology Industry and pharmaceutical industry. BIO and PhRMA have offices in Washington, D.C., with PhRMA also having locations in Japan and the United Arab Emirates.
• J&J is a member of the Personalized Medicine Coalition, a medical research advocacy group that lobbies on behalf of the pharmaceutical industry to increase funding for personalized medicine research and development.
• J&J is a member company of the National Pharmaceutical Council (NPC), a nonprofit that advocates for expanded research funding and innovation.

Research and development

J&J has provided research grants and major funding to the C. D. Howe Institute.

References

References

1. (February 13, 2025). "Johnson and Johnson 2024 Annual Report (Form 10-K)". [[U.S. Securities and Exchange Commission]].
2. "Johnson & Johnson".
3. SCHIFRIN", MATT. "Forbes' 2025 Global 2000 List - The World’s Largest Companies Ranked".
4. (2023-08-03). "Looking to Bet On Perfect AAA Credit Ratings? Play These ETFs".
5. (November 12, 2000). "Carbondale Area Native Founded Johnson & Johnson". The Times-Tribune.
6. (1999). "The Gentleman Rebel". Lillian Press.
7. (1983). "Biographical Dictionary of American Business Leaders". Greenwood Publishing Group.
8. (June 2013). "Joseph Lister and his 1876 tour of America". Annals of Surgery.
9. "World's Fair in Philadelphia : Johnson & Johnson Our Story".
10. Gordon, A. E.. (March 16, 1994). "The New Enterprise". The New Brunswick Times.
11. (February 24, 2020). "History of Johnson & Johnson – TheStreet".
12. (April 10, 2005). "From Band-Aids To Biotech (Published 2005)". [[The New York Times]].
13. (1888). "Pharmaceutische Rundschau". Fr. Hoffmann.
14. (2020). "Block's Disinfection, Sterilization, and Preservation". Lippincott Williams & Wilkins.
15. (1921). "Frederick Barnett Kilmer in History of Middlesex County, New Jersey 1664- 1920". Lewis Historical Publishing Company.
16. "1893, 1907, 1929 and Today".
17. Jenkins, Elizabeth. (May 11, 2017). "Oh, Baby! Why Johnson & Johnson Created Dr. Simpson's Maternity Packets".
18. "Lister's Towels, Johnson & Johnson, ads at MUM".
19. (February 26, 2020). "How did companies sell 'unmentionable' sanitary towels?". [[BBC News]].
20. (1898). "Red Cross Notes". Johnson & Johnson..
21. "Facts about disposable diapers as P&G celebrates 50 years in Cape County".
22. (March 28, 1911). "Peril of City Factories". Daily Home News.
23. "About Us".
24. "World War I Centennial: How the Great War Changed Johnson & Johnson".
25. "Epidemic Mask – Johnson & Johnson Our Story".
26. "History of Johnson & Johnson – FundingUniverse".
27. (1921). "Marketing Communications".
28. "Johnson & Johnson: Caring for People, Worldwide".
29. "1936 Magazine Print Advertisement Ortho Gynol Feminine Jelly Johnson & Johnson".
30. (August 9, 1943). "LIFE". [[Time (magazine).
31. (June 22, 2014). "Old School Products That Still Rock".
32. "First Peacetime Draft Enacted Just Before World War II".
33. (August 15, 2016). "World War I Draft Registration Cards".
34. "Johnson & Johnson Helped by the Healing Powers of Innovation, the Johnson Family Found a Health-Care Empire Inside the Family Medicine Chest. That's Opened up Endless Opportunities. April 1, 2003".
35. (January 31, 1968). "Robert Wood Johnson, 74, Dies; Chairman of Johnson & Johnson; Founder's Son Led Company until 1963 No. 2 Man on War Production Board (Published 1968)". [[The New York Times]].
36. "Our Credo".
37. (April 26, 2012). "Johnson & Johnson's new CEO emphasizes company credo at shareholder's meeting".
38. (December 31, 2019). "If You Invested $10,000 in Johnson & Johnson's IPO, This Is How Much Money You'd Have Now".
39. (May 6, 2015). "October 24, 1943 – COULDN'T KEEP HER IDEA DOWN {{!}} Chicago Tribune Archive".
40. (January 10, 2016). "ETHICON History".
41. "Robert Wood Johnson II Writes Or Forfeit Freedom {{!}} Johnson & Johnson Our Story".
42. (December 3, 2014). "A Comparison of Suturing Needles Available".
43. (March 14, 2019). "The Surgical Needle". Aesthetic Surgery Journal.
44. "Johnson & Johnson Expands to the Philippines {{!}} Johnson & Johnson Our Story".
45. "Expanding to India {{!}} Johnson & Johnson Our Story".
46. "Johnson & Johnson Private Limited – Manufacturer from Jogeshwari (E), Mumbai, India {{!}} About Us".
47. Check, The Company. "Johnson & Johnson Private Limited – Company Details {{!}} The Company Check".
48. (February 26, 2021). "A history of Johnson & Johnson".
49. (2024-02-06). "Fentanyl As A Dark Web Profit Center, From Chinese Labs To U.S. Streets".
50. "Ortho-Novum Oral Contraceptive".
51. Winokoor, Charles. "Johnson & Johnson's Codman & Shurtleff surgical instrument line sold to Indiana company".
52. (February 22, 2018). "RhoGAM at 50: A Columbia Drug Still Saving Lives of Newborns".
53. (April 1, 1971). "Modified Sickledex tube test: a specific test for S hemoglobin". Clinical Biochemistry.
54. (August 8, 2021). "Coronary Artery Bypass Graft Surgery".
55. (December 1974). "An evaluation of low voltage counterimmuno-electrophoresis for the detection of hepatitis-B antigen (HB Ag)". Journal of Clinical Pathology.
56. "Learning from our Late-Modern Legacy".
57. (2016). "New Brunswick, New Jersey, The Decline and Revitalization of Urban America". Rutgers University Press.
58. Abelson, Reed. (June 27, 2010). "Richard B. Sellars, Former Chief of Johnson & Johnson, Dies at 94". [[The New York Times]].
59. Hilts, Philip J.. (November 12, 1982). "Tylenol Is Reintroduced In Triple-Sealed Package". [[The Washington Post]].
60. (October 20, 2012). "Ralph S. Larsen – Robert Wood Johnson Foundation".
61. "Johnson & Johnson Reaches Eastern Europe {{!}} Johnson & Johnson Our Story".
62. "History of Johnson & Johnson – FundingUniverse".
63. "Johnson & Johnson Opens in Israel {{!}} Johnson & Johnson Our Story".
64. (February 21, 2012). "Johnson & Johnson CEO Weldon to step down in April". [[Reuters]].
65. (June 27, 2006). "J&J Buys Pfizer Consumer Healthcare Biz for $16.6 Billion".
66. (April 4, 2007). "AIDS drug Prezista performs well in new study". [[Reuters]].
67. "J&J's 800mg Prezista launched in UK – Pharmaceutical industry news".
68. (March 8, 2011). "Johnson & Johnson Acquires Vaccine Developer Crucell".
69. Murphy, Tom. "J&J CEO Gorsky to step down, company veteran to lead in 2022".
70. Perriello, Brad. (November 20, 2015). "J&J's Biosense Webster buys Coherex Medical and its WaveCrest anti-stroke device".
71. "Johnson & Johnson Vision to acquire TearScience".
72. (January 26, 2017). "Johnson & Johnson refills drug cabinet with $30 billion Actelion deal". [[Reuters]].
73. "Johnson & Johnson Medical GmbH Acquires Emerging Implant Technologies GmbH to Enhance Global Offering of Interbody Spine Implants".
74. Commissioner, Office of the. (March 24, 2020). "FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic".
75. (January 29, 2019). "SPRAVATO – Overview".
76. Research, National Center for Toxicological. (March 24, 2020). "FDA clears first contact lens with light-adaptive technology".
77. (August 19, 2020). "Johnson & Johnson to buy biotech Momenta in $6.5bn deal". [[Financial Times]].
78. (August 19, 2021). "J&J names Joaquin Duato as CEO effective Jan 3, replacing Alex Gorsky".
79. (December 22, 2022). "Johnson & Johnson Completes Acquisition of Abiomed".
80. Whooley, Sean. (December 22, 2022). "Johnson & Johnson completes $16.6B Abiomed acquisition".
81. Stych, Anne. (September 30, 2022). "Johnson & Johnson unveils new name for planned consumer products spinoff".
82. (November 12, 2021). "Johnson & Johnson to split into two companies".
83. Constantino, Annika Kim. (2023-05-04). "J&J's consumer-health spinoff Kenvue jumps 22% in public market debut".
84. (2023-07-24). "J&J starts share exchange offer for consumer health spin-off Kenvue". [[Reuters]].
85. Whooley, Sean. (2023-08-23). "Johnson & Johnson finalizes Kenvue spilt-off".
86. "Johnson & Johnson Financial Statements 2009-2025 {{!}} JNJ".
87. (April 26, 2023). "MSF: J&J must stop blocking generic versions of lifesaving TB drug".
88. ((The Wire Staff)). (2023-03-23). "J&J's Application to Extend Patent on Anti-Tuberculosis Drug Bedaquiline Rejected".
89. "Global Drug Facility Update on Access to Bedaquiline {{!}} Stop TB Partnership".
90. Constantino, Annika Kim. (2024-01-08). "J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion".
91. (2024-04-05). "Johnson & Johnson boosts heart device business with $12.5 billion Shockwave Medical deal".
92. (2024-04-05). "Johnson & Johnson to Acquire Shockwave Medical".
93. Loftus, Colin Kellaher and Peter. "Johnson & Johnson to Buy Shockwave Medical in $13.1 Billion Deal". WSJ.
94. (2024-05-16). "J&J Buys Proteologix for $850M, Bispecific Antibodies for Atopic Dermatitis".
95. "J&J creates open digital platform for surgical applications {{!}} MedTech Dive".
96. (2025-01-13). "J&J to buy neurological drugmaker Intra-Cellular for $14.6 billion".
97. (January 13, 2025). "J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal".
98. Vecchione, Anthony. (March 13, 2020). "J&J collaborates to accelerate COVID-19 vaccine development".
99. (April 6, 2020). "Prisma Health collaborates with Ethicon Inc. to make, distribute VESper Ventilator Expansion Splitter Device".
100. "Coronavirus: Johnson & Johnson vows to make 'not-for-profit' vaccine".
101. Stankiewicz, Kevin. (March 17, 2020). "J&J hopes to start human trials for coronavirus vaccine in November".
102. Vecchione, Anthony. (March 13, 2020). "J&J collaborates to accelerate COVID-19 vaccine development".
103. (March 19, 2020). "J&J's Tylenol production at maximum capacity as coronavirus boosts demand". [[Reuters]].
104. "Prisma Health, Ethicon to Build Ventilator Split Device for Emergency Use".
105. Coleman, Justine. (June 10, 2020). "Final testing stage for potential coronavirus vaccine set to begin in July".
106. (June 10, 2020). "Moderna, AstraZeneca and J&J coronavirus shots rev up for NIH tests beginning in July: WSJ". Fierce Pharma.
107. (July 16, 2020). "Johnson & Johnson to start human testing of COVID-19 vaccine next week". Fierce Pharma.
108. (August 5, 2020). "US to Pay Johnson and Johnson $1 Billion for COVID-19 Vaccine".
109. Johnson, Johnson &. "Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate".
110. (October 12, 2020). "Johnson & Johnson halts coronavirus vaccine trial because of sick volunteer.". [[The New York Times]].
111. (October 23, 2020). "Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.".
112. (October 23, 2020). "AstraZeneca, Johnson & Johnson resume late-stage Covid-19 vaccine trials".
113. Lovelace, Berkeley Jr.. (April 20, 2021). "Johnson & Johnson reports $100 million in quarterly sales from Covid vaccine".
114. Grant, Charley. (April 20, 2021). "Johnson & Johnson Shows Health Economy Is Nearing Full Strength". [[The Wall Street Journal]].
115. "Innovation Centers {{!}} Johnson & Johnson Innovation".
116. Waldron, James. (September 20, 2022). "Johnson & Johnson opens 400-person R&D facility to strengthen Bay Area presence".
117. Waldron, James. (September 20, 2022). "Johnson & Johnson opens 400-person R&D facility to strengthen Bay Area presence".
118. Levin, Jennifer. (March 13, 2013). "Johnson & Johnson Announces Opening of London Innovation Centre".
119. "What If We Could Stop Lung Cancer Before It Starts?".
120. "J&J opens new research hub near San Francisco".
121. Lawrence, Stacy. (October 18, 2016). "J&J to create new Texas center to develop 'breakthrough' med tech".
122. "Innovation Centers {{!}} Johnson & Johnson Innovation".
123. "Pharmaceutical Products".
124. "MedTech".
125. "0000200406-21-000008 {{!}} 10-K {{!}} Johnson & Johnson".
126. (December 1, 2008). "J&J to buy breast implant firm Mentor for $1.1 billion". [[Reuters]].
127. (September 8, 2021). "DePuy Synthes Product, Inc. Leases Palm Beach Gardens Office Space Expanding South Florida Footprint".
128. (January 10, 2016). "ETHICON History".
129. "Johnson & Johnson: Shareholders Board Members Managers and Company Profile {{!}} US4781601046 {{!}} MarketScreener".
130. "Johnson & Johnson Revenue 2010-2024 {{!}} JNJ".
131. "Johnson & Johnson: Number of Employees 2010-2024 {{!}} JNJ".
132. "Institute for Clinical and Economic Review Announces Most Significant Drug-Price Hikes Unsupported by New Clinical Evidence in US".
133. "Governance - Corporate governance overview {{!}} Johnson & Johnson".
134. "Our Leadership Team".
135. Rivas, Kayla. (August 20, 2021). "J&J's new CEO Joaquin Duato: What to know".
136. "Joaquin Duato to Take Over as Chief Executive Officer of Johnson & Johnson".
137. (December 2022). "Johnson & Johnson CEO Joaquin Duato to take additional role of chairman".
138. "Johnson & Johnson (JNJ) Stock Major Holders - Yahoo Finance".
139. "Green Rankings".
140. "Johnson & Johnson Official Site".
141. [http://www.ens-newswire.com/ens/dec2004/2004-12-08-09.asp Environment New Service], December 8, 2004. Retrieved May 4, 2008
142. (March 27, 2008). "Coop America".
143. "Department of Environmental Protection". Commonwealth of Pennsylvania.
144. "Johnson & Johnson - Greenhouse Gas Emissions: Scope 1, 2 & 3 Data".
145. (March 23, 2002). "Tylenol made a hero of Johnson & Johnson : The recall that started them all". [[The New York Times]].
146. [http://www.latimes.com/business/la-fi-lazarus11-2010feb11,0,3768807.column Toyota, what's so hard about doing the right thing?], ''[[Los Angeles Times]]'', February 11, 2010
147. Jennifer Latson for Time Magazine September 29, 2014 [https://time.com/3423136/tylenol-deaths-1982/ How Poisoned Tylenol Became a Crisis-Management Teaching Model]
148. Judith Rehak for The New York Times. March 23, 2002 [https://www.nytimes.com/2002/03/23/your-money/23iht-mjj_ed3_.html Tylenol made a hero of Johnson & Johnson : The recall that started them all]
149. (May 2, 2010). "Warning As Baby Medicines Are Recalled". Sky News.
150. (May 14, 2011). "Out of joint: The story of the ASR".
151. (May 2025). "FDA. Concerns about metal-on-metal hip implant systems. 2011".
152. (March 8, 2013). "J.&J. Loses First Case Over Faulty Hip Implant". [[The New York Times]].
153. [http://arthritis.webmd.com/news/20091229/tylenol-recall-expands Tylenol Recall Expands] {{Webarchive. link. (January 27, 2014 , WebMD Health News, January 18, 2010)
154. "McNeil Consumer Healthcare Announces Voluntary Recall Of One Product Lot Of TYLENOL® Extra Strength Caplets 225 Count Distributed In The U.S.".
155. "10-cv-2033, D. NJ., Sept. 29, 2011".
156. [http://www.boston.com/business/healthcare/2012/07/12/shareholders-reach-tentative-deal-lawsuit/6wGyy1rFpcVUR6OEdvYPTL/story.html J&J, shareholders reach tentative deal in lawsuit] By Linda A. Johnson, AP Business Writer / July 12, 2012
157. Gregory Wallace. (November 4, 2013). "Johnson & Johnson to pay $2 billion for false marketing".
158. [https://www.nytimes.com/2012/04/12/business/drug-giant-is-fined-1-2-billion-in-arkansas.html?_r=0 J.&J. Fined $1.2{{nbs}}Billion in Drug Case] NY Times, By KATIE THOMAS Published: April 11, 2012
159. (January 16, 2010). "Justice suit accuses Johnson & Johnson of paying kickbacks". [[The Washington Post]].
160. (January 15, 2010). "Johnson & Johnson Accused of Drug Kickbacks". [[The New York Times]].
161. [https://www.bloomberg.com/news/2012-06-11/j-j-said-to-pay-2-2-billion-to-end-risperdal-sales-probe.html J&J Said to Agree to $2.2{{nbsBillion Drug Marketing Accord] Bloomberg News. By Margaret Cronin Fisk, Jef Feeley & David Voreacos{{sndJune 11, 2012
162. (November 4, 2015). "Johnson & Johnson to Pay More Than $2.2 Billion to Resolve Criminal and Civil Investigations". United States Department of Justice.
163. [https://www.nytimes.com/2008/11/25/health/25psych.html Research Center Tied to Drug Company] By Gardiner Harris, The New York Times, 2008
164. "Johnson & Johnson".
165. (April 8, 2011). "J&J settles U.S., UK bribery, kickback charges". [[Reuters]].
166. (April 7, 2011). "SEC Charges Johnson & Johnson With Foreign Bribery". SEC.
167. "J&J Reaches $33 Million Settlement with States".
168. (May 24, 2017). "Johnson & Johnson settles drug manufacturing probe by US states for $33 million". [[The Economic Times]].
169. "UPDATE 1-J&J settles drug manufacturing probe by U.S. states for $33 mln". [[Business Insider]].
170. "Trademark Status & Document Retrieval". uspto.gov.
171. "1205.01 Statutory Protection".
172. Sturges, Wesley. (1957). "The Legal Status of the Red Cross". Michigan Law Review.
173. "§ 706. Red Cross".
174. [http://www.icrc.org/ihl.nsf/NORM/D6B53F5B5D14F35AC1256402003F9920?OpenDocument U.S. reservations to the 1949 Geneva Conventions] ([[International Committee of the Red Cross]] website)
175. (August 10, 2007). "American Red Cross Defends Use of Emblem and Mission".
176. [https://www.wsj.com/articles/SB118662527980592590 "Red Cross Is Sued by J&J Over Signature Emblem"] ''[[The Wall Street Journal]]'' August 9, 2007
177. (June 18, 2008). "Claim Over Red Cross Symbol Is Settled". [[The New York Times]].
178. [https://www.wsj.com/articles/SB10001424052748704107204575039430685168478 Boston Scientific to Pay J&J $1.73B to Settle Stent Patent Disputes], ''[[The Wall Street Journal]]'', February 2, 2010
179. [https://www.reuters.com/article/us-johnson-johnson-boston-scient-trial-idUSKCN0J30CS20141119 J&J seeks over $5{{nbsbillion in damages from Boston Scientific at trial]. [[Reuters]], November 19, 2014
180. [https://www.bloomberg.com/apps/news?pid=newsarchive&sid=aF0Qoxe0JCiw Abbott Told to Pay Record $1.67{{nbs}}billion Award to J&J], ''Bloomberg News'', June 29, 2009
181. [https://www.bloomberg.com/news/2010-11-02/abbott-challenges-1-67-billion-patent-loss-to-j-j-over-arthritis-therapy.html Abbott Challenges $1.67{{nbsbillion Patent Loss to J&J Over Humira], ''Bloomberg News'', November 2, 2010
182. until the 2013 decision against Teva in favor of [[Takeda Pharmaceutical Company
183. "abbott-wins-reversal-of-j-j-s-1-67-billion-patent-victory". [[Bloomberg News.
184. (May 25, 2016). "States file lawsuit against Johnson & Johnson over pelvic mesh implants".
185. (July 4, 2017). "Vaginal mesh risks downplayed by Johnson & Johnson, court told".
186. (November 27, 2018). "Pharma giant sold mesh implant despite pain warnings". [[The Guardian]].
187. (September 12, 2022). "Johnson & Johnson to pay pelvic mesh victims record $300m settlement".
188. (March 9, 2021). "Appeal in Ethicon pelvic mesh class action – what risks need to be disclosed?".
189. (October 17, 2019). "Johnson & Johnson to Pay $117{{nbs}}Million Over Surgical Device Marketing". Dow Jones and Company.
190. (2025-02-18). "Johnson & Johnson begins battle over $10 billion case linking baby powder to cancer".
191. (June 1, 2021). "J&J to Pay $2.1 Billion Talc Award as Top Court Nixes Appeal". [[Bloomberg News]].
192. (February 24, 2016). "Johnson & Johnson hit with $72m damages in talc-cancer case". [[BBC News]].
193. [https://www.bloomberg.com/features/2016-baby-powder-cancer-lawsuits/ Johnson & Johnson Has a Baby Powder Problem] Bloomberg, Retrieved April 20, 2017.
194. (August 21, 2017). "J&J ordered to pay $417{{nbs}}million in trial over talc cancer risks". [[Reuters]].
195. (October 17, 2017). "Missouri appeals court tosses out $72 million Johnson & Johnson talcum powder verdict".
196. (July 13, 2018). "Johnson & Johnson ordered to pay $4.7 billion to women who say baby powder gave them cancer". [[The Washington Post]].
197. (August 7, 2018). "Johnson and Johnson removes chemicals to make products safer".
198. (December 14, 2018). "Johnson & Johnson knew for decades that asbestos lurked in some of its baby powder".
199. (December 19, 2018). "J&J loses its battle to overturn a $4.7B baby powder verdict".
200. (February 25, 2016). "The Johnson and Johnson Talc Cancer Case".
201. (December 23, 2019). "St. Louis jury sides with Johnson & Johnson in talc case". [[The Seattle Times]].
202. (December 10, 2019). "Johnson & Johnson CEO refuses to attend US hearing on carcinogens".
203. Albert, Victoria. (May 20, 2020). "Johnson & Johnson to discontinue sales of talc-based baby powder in U.S., Canada".
204. Stempel. (November 4, 2020). "Johnson & Johnson fails to overturn $2.12 billion baby powder verdict, plans Supreme Court appeal".
205. (June 23, 2020). "Women With Cancer Awarded Billions in Baby Powder Suit".
206. (June 1, 2021). "Supreme Court won't review $2 billion verdict against Johnson & Johnson in talc powder case".
207. (June 1, 2021). "Supreme Court Won't Consider Johnson & Johnson Challenge to Baby Powder Judgment".
208. (June 1, 2021). "Supreme Court Says A $2 Billion Verdict In A Baby Powder Cancer Case Should Remain".
209. Walters, Natalie. (October 14, 2021). "Johnson & Johnson forms new subsidiary to take ovarian cancer claims into bankruptcy court". [[The Dallas Morning News]].
210. "J&J is using a bankruptcy maneuver to block lawsuits over baby powder cancer claims". [[NPR]].
211. (August 12, 2022). "J&J to replace talc-based powder with cornstarch after cancer lawsuits". [[BBC News]].
212. Blohm, Eike. "Experimenting on Prisoners: New California Lawsuits Reveal Old Abuses".
213. Feeley, Jef. (March 7, 2022). "J&J's Controversial Prison Testing Resurfaces in Baby Powder Lawsuits". [[Bloomberg News.
214. "New Docs Show J&J Funded Study That Injected Inmates With Asbestos In 1971".
215. Feeley, Jef. (2022-03-08). "J&J's controversial prison testing with a Penn doctor resurfaces in baby powder lawsuits".
216. (April 5, 2023). "Johnson & Johnson offers $9bn to settle talc claims". [[BBC News]].
217. Knauth, Dietrich. (18 Feb 2025). "J&J begins crucial battle over $10 billion baby powder settlement".
218. Dunleavy, Kevin. (2025-10-07). "J&J will appeal $966M award by LA jury in talcum powder lawsuit".
219. (2025-10-28). "J&J Talc Cancer Suits Rise 17% After Failed Settlement Push".
220. (March 2, 2018). "DOJ to Support Lawsuits Against Companies Selling Opioids". Advantage Business Media.
221. (March 12, 2019). "Johnson & Johnson acted as opioid kingpin, Oklahoma attorney general says". [[CNN]].
222. (August 17, 2018). "Trump Insurance For Johnson & Johnson".
223. "11 Idaho counties take on Walmart, CVS, drug companies in opioid lawsuit".
224. (May 27, 2019). "First Big Trial in Opioid Crisis Set to Kick Off in Oklahoma". [[The Wall Street Journal]].
225. (August 26, 2019). "Oklahoma wins case against drugmaker in historic opioid trial". [[CNN]].
226. "Johnson & Johnson to Pay Ohio Counties $20.4M Opioid Settlement".
227. Raymond, Nate. (January 27, 2022). "Most U.S. local governments opt to join $26 bln opioid settlement". [[Reuters]].
228. Raymond, Nate. (November 16, 2021). "Washington state, in $95 billion opioid trial, blames drug distributors for crisis". [[Reuters]].
229. (October 1, 2019). "Johnson & Johnson Agrees to Settle Ohio Opioid Lawsuits for $20.4 Million". Dow Jones and Company.
230. (2018). "Report for the Academic Year 2017–2018".
231. "Corporate Partners".
232. Boyle, Kelsi. "Our Supporters".
233. "2020 Donors".
234. "Our Network".
235. "About".
236. "Johnson & Johnson {{!}} BIO".
237. "Current Members".
238. "Members".
239. C. D. Howe Institute. "Annual Report 2019".